Earn CME: https://www.naccme.com/program/19-cpc-101-2 This webcast features a presentation by Dr. Gabriella Hobbs that examines the most recent evidence-based guidelines to optimize individualized tyrosine kinase inhibitor (TKI) selection for chronic myeloid leukemia (CML) patients based on disease phase, treatment history, genetic mutation profile, and comorbidities, © 2019 NACCME, an HMP Company
Strategies in Chronic Myeloid Leukemia: The Evolving Treatment Landscape
